Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab for Pain in Chronic Pancreatitis
NCT01146561Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2010
- Primary completion
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic pancreatitis (CP) comparing Tanezumab 20 mg with Placebo (2 arms). Primary endpoint: Change From Baseline in Average Chronic Pancreatitis Pain Intensity Score. Started Oct 2010; status: terminated.
02
Drugs
tanezumab
03
Conditions
chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT01146561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146561.